Rozlytrek 200 mg hard capsules
GO40782
Phase 2 small_molecule active
Quick answer
Rozlytrek 200 mg hard capsules for Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements is a Phase 2 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active